Maturing pharmacogenomic factors deliver improvements and cost efficiencies
Cambridge Prisms: Precision Medicine · 2023
DOI: 10.1017/pcm.2022.3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cambridge Prisms: Precision Medicine, 2023. Verfasst von Joseph P Jarvis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Coriell Life Sciences, Philadelphia, PA, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An ever-expanding annotation of the human genome sequence continues to promise a new era of precision medicine. Advances in knowledge management and the ability to leverage genetic information to make clinically relevant, predictive, diagnostic, and targeted therapeutic choices offer the ability to improve patient outcomes and reduce the overall cost of healthcare. However, numerous barriers have resulted in a modest start to the clinical use of genetics at scale. Examples of successful deployments include oncologic disease treatment with targeted prescribing; however, even in these cases, genome-informed decision-making has yet to achieve standard of care in most major healthcare systems. In the last two decades, advances in genetic testing, therapeutic coverage, and clinical decision support have resulted in early-stage adoption of pharmacogenomics – the use of genetic information to routinely determine the safety and efficacy profile of specific medications for individuals. Here, through their complicated histories, we review the current state of pharmacogenomic testing technologies, the information tools that can unlock clinical utility, and value-driving implementation strategies that represent the future of pharmacogenomics-enabled healthcare decision-making. We conclude with real-world economic and clinical outcomes from a full-scale deployment and ultimately provide insight into potential tipping points for global adoption, including recent lessons from the rapid scale-up of high-volume test delivery during the global SARS-CoV2 epidemic.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Coriell Life Sciences, Philadelphia, PA, USA.
- Thermo Fisher Scientific, Waltham, MA, USA.
ORCID-Profile: Jeffrey A Shaman
Zitieren
APA
Jarvis, J. P., Megill, S. E., Silvester, P., & Shaman, J. A. (2023). Maturing pharmacogenomic factors deliver improvements and cost efficiencies. Cambridge Prisms: Precision Medicine. https://doi.org/10.1017/pcm.2022.3
Vancouver
Jarvis JP, Megill SE, Silvester P, Shaman JA. Maturing pharmacogenomic factors deliver improvements and cost efficiencies. Cambridge Prisms: Precision Medicine. 2023. doi:10.1017/pcm.2022.3
BibTeX
@article{Jarvis2023,
author = {Jarvis, Joseph P and Megill, Scott E and Silvester, Peter and Shaman, Jeffrey A},
title = {Maturing pharmacogenomic factors deliver improvements and cost efficiencies},
journal = {Cambridge Prisms: Precision Medicine},
year = {2023},
doi = {10.1017/pcm.2022.3}
}
EUVIMED